[Administration of clarithromycin (CAM) to non-small cell lung cancer].
Majima
T
T
Mikasa
K
K
Sakamoto
M
M
Hamada
K
K
Konishi
M
M
Maeda
K
K
Yoshimoto
E
E
Murakawa
K
K
Takahashi
K
K
Kita
E
E
Narita
N
N
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D017291:Clarithromycin / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL
D000900:Anti-Bacterial Agents; D007155:Immunologic Factors; D016753:Interleukin-10; D018664:Interleukin-12; D007371:Interferon-gamma; D017291:Clarithromycin